Abstract
Background
Nighttime gastrointestinal reflux disease (GERD) prevalence and severity estimates vary substantially across studies.
Methods
We assessed nighttime GERD (NTG) prevalence and symptom frequency and severity through a web survey of US adults, using the GERD Symptom and Medication Questionnaire (GERD-SMQ), a validated symptom questionnaire. NTG was based on episodes of nighttime heartburn per week and time of occurrence. Symptom severity and impact were assessed and compared for GERD cases with and without NTG.
Results
GERD prevalence among respondents (n = 2,603) was 27%. Forty-five percent of symptomatic GERD respondents had NTG. Among respondents with both daytime and nighttime symptoms, 51% reported that nighttime symptoms were more bothersome. NTG respondents reported greater disease severity compared with those without (P < 0.0001).
Conclusions
NTG symptoms are very common among those identified with GERD. People with nighttime symptoms have greater disease severity than those with exclusively or primarily daytime symptoms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
A Gallup Organization National Survey: Heartburn Across America. Princeton, NJ: The Gallup Organization; 1988.
Locke GR 3rd, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted county, Minnesota. Gastroenterology. 1997;112:1448–1456.
Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis. 1976;21:953–956.
Freidin N, Fisher MJ, Taylor W, et al. Sleep and nocturnal acid reflux in normal subjects and patients with reflux oesophagitis. Gut. 1991;32:1275–1279.
Orr WC, Allen ML, Robinson M. The pattern of nocturnal and diurnal esophageal acid exposure in the pathogenesis of erosive mucosal damage. Am J Gastroenterol. 1994;89:509–512.
Shaker R, Castell DO, Schoenfeld PS, et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003;98:1487–1493.
Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med. 2001;161:45–52.
Katz PO. Nocturnal reflux: assessing and addressing the problem. Pract Gastroenterol. 2005;29:30, 32, 35, 36, 38, 39.
Kothawala P, McGuigan JE, Lange S, et al. Variations in definitions of nighttime GERD: a systematic review. Gastroenterology. 2008;134:A-175.
Ofman JJ, Shaw M, Sadik K, et al. Identifying patients with gastroesophageal reflux disease: validation of a practical screening tool. Dig Dis Sci. 2002;47:1863–1869.
U.S. Census Bureau. United States General Demographic Characteristics: 2004. Data Set: 2004 American Community Survey. Available online at: http://factfinder.census.gov/servlet/ADPTable?_bm=y&-geo_id=01000US&-ds_name=ACS_2004_EST_G00_&-_lang=en&-_caller=geoselect&-format=; 2004.
Dubois RW, Aguilar D, Fass R, et al. Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity. Aliment Pharmacol Ther. 2007;25:487–500.
Author information
Authors and Affiliations
Corresponding author
Additional information
Dr. Dean had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Statement of Interests
Statement of Interests
Authors’ Declaration of Personal Interests
-
(i)
Dr. Fass has served as a consultant, speaker, or member of an advisory board, or has received research funding from Wyeth, AstraZeneca, Altana, Takeda, Eisai, Xenoport, Procter & Gamble, Vecta, Addex, and GlaxoSmithKline. Dr. McGuigan has served as a speaker, a consultant, and an advisory board member for Wyeth Pharmaceuticals, and has received research funding from Wyeth Pharmaceuticals. Dr. Johnson has served as a consultant or member of an advisory board, or has received research funding from Wyeth, AstraZeneca, Santarus, and Tap Pharmaceutical Companies. Dr. Orr has served as a consultant or member of an advisory board or speaker’s bureau for Wyeth, AstraZeneca, Santarus, and TAP.
-
(ii)
Dr. Morgenstern is an employee of Wyeth Pharmaceuticals. Dr. Yan was an employee of Wyeth Pharmaceuticals at the time of drafting this manuscript. Messrs. Aguilar and Calimlim and Drs. Dubois and Dean are employees of Cerner LifeSciences, a consulting company that provides services to the pharmaceutical industry.
-
(iii)
Drs. Morgenstern and Yan own stocks and shares in Wyeth Pharmaceuticals.
Declaration of Funding Interests
-
(i)
This study was funded in full by Wyeth Pharmaceuticals.
-
(ii)
The writing or preparation of this paper was funded in full by Wyeth Pharmaceuticals.
-
(iii)
Initial data analyses were undertaken by no one besides the authors, affiliated and funded as stated above.
-
(iv)
Writing support was provided by no one besides the authors, affiliated and funded as stated above.
Rights and permissions
About this article
Cite this article
Dean, B.B., Aguilar, D., Johnson, L.F. et al. The Relationship Between the Prevalence of Nighttime Gastroesophageal Reflux Disease and Disease Severity. Dig Dis Sci 55, 952–959 (2010). https://doi.org/10.1007/s10620-009-0885-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-009-0885-2